

Is the U.S. Biosimilar Industry Falling Behind?



87 percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies' stances on selling and manufacturing biosimilars.

SELLING

MANUFACTURING

"To the best of your knowledge, what is your company's current stance on selling biosimilars? (Select all that apply)"

"To the best of your knowledge, what is your company's current stance on manufacturing biosimilars? (Select all that apply)"

NORTH AMERICA (n=124)



25%
Currently sell biosimilars



21%
Plan to sell biosimilars



10%
Currently evaluating selling biosimilars



58%
Have no plans to sell biosimilars



22%
Currently manufacture biosimilars



16%
Plan to manufacture biosimilars



7%
Currently evaluating biosimilar manufacturing



66%
Have no plans to manufacture biosimilars

EUROPE (n=47)



32%
Currently sell biosimilars



36%
Plan to sell biosimilars



19%
Currently evaluating selling biosimilars



34%
Have no plans to sell biosimilars



38%
Currently manufacture biosimilars



26%
Plan to manufacture biosimilars



23%
Currently evaluating biosimilar manufacturing



34%
Have no plans to manufacture biosimilars